Jump to content

TC-2216

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by DMacks (talk | contribs) at 09:50, 23 March 2024 (auto mw). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
TC-2216
Identifiers
  • 8-pyridin-3-yl-1,8-diazaspiro[4.4]nonane
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H17N3
Molar mass203.289 g·mol−1
3D model (JSmol)
  • N1CCCC1(CC2)CN2c3cnccc3
  • InChI=1S/C12H17N3/c1-3-11(9-13-6-1)15-8-5-12(10-15)4-2-7-14-12/h1,3,6,9,14H,2,4-5,7-8,10H2
  • Key:NXIPMBQVNTWEEX-UHFFFAOYSA-N
  (verify)

TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and was researched for the treatment of anxiety and depression.[1] It was unsuccessful as a therapeutic but is still used in pharmacological research as an alpha4beta2-selective antagonist.[2]

References

[edit]
  1. ^ Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
  2. ^ Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, Xie J, Bencherif M (2008). "TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity". CNS Neuroscience & Therapeutics. 14 (4): 266–77. doi:10.1111/j.1755-5949.2008.00054.x. PMC 6494058. PMID 19040552.